SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc is seeing intense investor debate as it navigates a challenging drawdown period marked by significant share dilution and aggressive short-selling activity. Despite this, bulls remain focused on the company's expanding backlog, recent defense-focused partnerships with firms like Palantir and Lockheed Martin, and increasing government spending on autonomous drone technology.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martin is trending due to a flurry of new Department of Defense contract wins and heightened investor focus on the company's long-term role in the 'Golden Dome' missile defense initiative. The community is actively debating the stock's performance amid shifting geopolitical tensions, with discussions centering on whether the recent pullbacks offer a strategic entry point or if the sector faces broader structural headwinds.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grumman is trending as investors weigh strong backlog growth and strategic roles in major defense programs like the B-21 Raider against concerns regarding recent capital expenditure and sector-wide regulatory pressure. The community is actively debating the company's long-term valuation compared to high-growth autonomous drone players, while monitoring how upcoming government contract decisions and budget cycles will influence performance.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

The Grayscale Bitcoin Mini Trust ETF is trending as the community debates Bitcoin's long-term utility versus its status as a legacy crypto asset amidst significant market volatility. Conversations are heavily focused on the struggle for support near key liquidity levels, with traders debating whether institutional adoption stabilizes the asset or if it remains vulnerable to broader macro pressures and rotation into AI-related equities.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike is trending following a positive fiscal first-quarter report that featured a beat on earnings, an ARR guidance raise, and the announcement of a 4-for-1 stock split. Despite the strong fundamental performance, the shares experienced significant downward pressure as investors reacted to elevated expectations following a rapid year-to-date rally, leading to active debate regarding the company's valuation versus its growth sustainability.

Re is an internet-native marketplace for insurance capital. It connects eligible capital providers with fully collateralized reinsurance activity conducted through licensed insurance entities. Blockchain infrastructure makes collateral, reserves, and selected operating data verifiable onchain. RE is the governance token of the Re Protocol. It governs protocol upgrades, technical permissions, committee formation, reporting standards, incentive policy, and governance procedures. Underwriting, claims, pricing, reserve decisions, and regulated operations remain with qualified professionals and licensed entities.

RE is trending as investors rally around its real-world utility in the reinsurance market and institutional backing, with community members actively discussing a potential squeeze and the prospect of the token breaking through key psychological price levels. Discussions are heavily focused on the coin's low circulating supply, recent exchange listings, and the belief that it is an early-stage asset with significant upside potential.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is gaining intense momentum as investors anticipate a pivotal Phase 3 REGAL trial data readout, with the community closely tracking the 80th clinical event as a major catalyst. Discussions are dominated by speculation over a potential high-premium buyout, driven by the stock's role as a platform asset for multiple cancer indications and significant short interest that may fuel an explosive move.

Zoracles

Zoracles is facing heavy selling pressure as investors struggle with volatility and the wider market correction driven by Bitcoin's recent price action. Despite the bearish sentiment and frustrations over price stagnation, the community remains divided, with many long-term holders advocating for patience and dollar-cost averaging while awaiting a potential rebound fueled by future catalyst events.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc - Ordinary Shares - 144A

Nasdaq Inc

Nasdaq is currently trending as investors weigh strong capital markets activity and record-breaking fundraising against broader market volatility and AI-driven sector rotations. The community is actively discussing the platform's role in the evolving IPO landscape, the impact of new AI model efficiency on tech valuations, and the structural implications of expanded trading infrastructure.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending as investors rotate into defensive healthcare leaders, supported by analyst upgrades highlighting improved medical cost trends and momentum near 52-week highs. The community is actively debating the stock's valuation at these elevated levels while closely monitoring key resistance zones for potential trend continuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics 

Regeneron expands its CytomX partnership to develop conditionally activated bispecific cancer therapies, with potential milestones nearing $4 billion.

CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of +29.58% and +193.76%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Beats Revenue Estimates

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of +3.47% and +8.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

CytomX Therapeutics (CTMX) Expected to Announce Quarterly Earnings on Thursday

CytomX Therapeutics (NASDAQ:CTMX) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-cytomx-therapeutics-inc-stock...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of "Moderate Buy" from Analysts

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and nine have assigned...

Wall Street Zen Downgrades CytomX Therapeutics (NASDAQ:CTMX) to Strong Sell

Wall Street Zen lowered shares of CytomX Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday...

CytomX Therapeutics (NASDAQ:CTMX) Stock Price Crosses Below 50-Day Moving Average - Here's What Happened

CytomX Therapeutics (NASDAQ:CTMX) Share Price Passes Below 50-Day Moving Average - What's Next...

Traders Buy High Volume of CytomX Therapeutics Put Options (NASDAQ:CTMX)

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) was the recipient of some unusual options trading activity on Thursday. Stock traders acquired 13,090 put options on the company. This...

CytomX Therapeutics (NASDAQ:CTMX) Stock Price Up 6.3%  - Time to Buy?

CytomX Therapeutics (NASDAQ:CTMX) Trading Up 6.3% - What's Next...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Moderate Buy" by Brokerages

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten brokerages that are covering the stock, MarketBeat Ratings...

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

CytomX Therapeutics Inc

CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

CTMXCytomX Therapeutics Inc

Fundamentals

Latest CTMX News